Mustang Bio, Inc..
MBIO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating innovative technologies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The company develops cell and gene therapies based on proprietary chimeric antigen receptor (CAR) T ce...Show More
Better Health for All
0
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for difficult-to-treat cancers, rare genetic diseases, and autoimmune diseases.
1
Its entire business is devoted to health improvement, with a pipeline including MB-106 for hematologic malignancies and autoimmune diseases, MB-109 for recurrent glioblastoma, and gene therapies for RAG1-SCID and X-linked severe combined immunodeficiency.
2
MB-106 demonstrated a 96% overall response rate and 75% complete response rate in a Phase 1 trial for hematologic malignancies.
3
Clinical trials for MB-101, MB-106, and MB-108 have shown favorable safety profiles, with treatments being well tolerated, no dose-limiting toxicities, and no treatment-related deaths.
4
For MB-106, nine out of ten patients experienced Grade 1 or 2 CRS, and one patient experienced Grade 1 ICANS, with no Grade 3 or 4 events.
5
The company's in vivo CAR-T platform technology aims to enable an off-the-shelf product, potentially eliminating the need for ex vivo T-cell isolation and expansion.
6
The company includes a "Summary of Risk Factors" and "Special Cautionary Note Regarding Forward-Looking Statements" detailing potential risks and uncertainties in its documents.
7
Mustang Bio is subject to HIPAA and HITECH regulations concerning health information privacy, security, and transmission.
8
Clinical testing must meet requirements for institutional review board oversight, informed consent, and good clinical practices.
9
Fair Money & Economic Opportunity
0
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies, not a financial institution.
1
The company does not offer lending, deposit, or other financial services to consumers.
2
Therefore, all KPIs related to financial products, services, and customer financial outcomes are not applicable to its core business model. The rubric's '0' tier explicitly covers companies whose core business lies outside finance or do not offer the relevant financial products or services.
Fair Pay & Worker Respect
0
Mustang Bio's employee satisfaction rating is 3.3 out of 5 stars, based on 21 Glassdoor reviews.
1
This translates to approximately 66 out of 100 for worker engagement. The company has no specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights mentioned in the provided articles.
2
Employee perception of compensation and benefits is low, rated at 2.8 out of 5 stars, and this rating decreased by 7% over the last 12 months.
3
As of January 2024, the company had 78 employees, but announced layoffs affecting 81% of its staff, to be completed by Q2 2024.
4
Due to the small and significantly reduced workforce, a meaningful voluntary turnover rate cannot be assessed.
Fair Trade & Ethical Sourcing
0
No information regarding fair trade and ethical sourcing practices, such as fair-trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, was found in the provided articles.
1
Honest & Fair Business
-30
Mustang Bio, Inc. has indicated no financial restatements for the fiscal years ended December 31, 2022, 2024, and the period ended June 30, 2025.
1
The company's financial statements are audited by KPMG LLP, with audit fees of approximately $412,000 for 2024 and $372,000 for 2023.
2
However, the auditor attestation for Internal Control over Financial Reporting (ICFR) was flagged as false in the 10-K Annual Report for December 31, 2024.
3
The board has determined that three directors (Adam Chill, Neil Herskowitz, and Michael Zelefsky, M.D.) are independent, but Fortress controls a voting majority of common stock, and shared directors with Fortress could create conflicts of interest.
4
The company acknowledges the need to comply with the Foreign Corrupt Practices Act (FCPA) and mentions the risk of employee fraud or misconduct, but there is no evidence of specific training frequency or effectiveness metrics for its anti-corruption policy.
5
Kind to Animals
0
The provided articles do not contain specific, concrete evidence regarding Mustang Bio, Inc.'s (MBIO.US) performance across any of the 'Kind to Animals' KPIs. While the articles discuss broader industry trends and regulatory changes related to animal testing, such as the FDA Modernization Act and the increasing use of New Approach Methodologies (NAMs), these facts pertain to the general regulatory environment and other companies (e.g., bit.bio, Pistoia Alliance survey respondents), not to MBIO.US's specific actions, policies, or performance metrics.
1
There is no information on MBIO.US's cruelty-free certifications, use of alternative testing methods, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy, animal testing volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.
2
No War, No Weapons
0
Mustang Bio, Inc. is a biopharmaceutical company focused on cell and gene therapies.
1
All provided articles explicitly state that the company has no defense or arms-related activities, no dual-use products, no defense procurement, and is not subject to the Arms Trade Treaty.
2
The articles consistently indicate that all KPIs related to 'No War, No Weapons' are 'Not Applicable (N/A)' to the company's operations, aligning directly with the '0: N/A' tier in the rubric for each KPI.
3
Planet-Friendly Business
0
The provided articles, which include financial reports (Form 10-Q and 10-K) and a CSRHub description, do not contain any specific, quantitative data points related to environmental performance or sustainability metrics. The articles explicitly state a lack of information on ESG metrics, emissions, renewable energy, water use, or waste diversion, making it impossible to assess Mustang Bio, Inc. against the 'Planet-Friendly Business' KPIs.
1
Respect for Cultures & Communities
0
The provided article focuses exclusively on Mustang Bio's clinical trials for cancer therapies and explicitly states that it contains no data relevant to the company's relationships with indigenous or local communities, or its respect for cultures and communities.
1
Consequently, no evidence is available to assess any of the KPIs for this ethical value.
Safe & Smart Tech
-20
The company states it does not sell, rent, or loan any information to any third party, and its policy indicates personal information is not shared.
1
Users can set their browser to refuse cookies.
2
The company acknowledges that its internal computer systems and those of third parties are vulnerable to damage from computer viruses and unauthorized access, and it engages third parties to assess and improve security processes.
3
The company received a deficiency letter from Nasdaq in March 2024 for not complying with the minimum stockholders’ equity requirement and in May 2024 for its common stock bid price falling below $1.00 for 31 consecutive business days.
4
It also received a notice from Nasdaq in March 2024 regarding non-compliance with the market value of listed securities requirement.
5
Zero Waste & Sustainable Products
0
No specific data points related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles for Mustang Bio, Inc.
1